Oral mucosa and therapy of recurrent aphthous stomatitis

Ceska a Slovenska Farmacie

Volumn 62, Issue 1, 2013, Pages 12-18

  Landová, Hana ^a   Daněk, Zdeněk ^b   Gajdziok, Jan ^a   Vetchý, David ^a   Štembírek, Jan ^c  

^a UNIVERSITY OF VETERINARY AND PHARMACEUTICAL SCIENCES   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^c UNIVERSITY HOSPITAL OSTRAVA   (Czech Republic)

Author keywords

Mucoadhesive dosage forms; Oral mucosa; Recurrent aphthous stomatitis; Therapy

Indexed keywords

AMINOSALICYLIC ACID; AMLEXANOX; BENZYDAMINE; BETAMETHASONE; CHLORHEXIDINE; COLCHICINE; CROMOGLYCATE DISODIUM; DYCLONINE; FLUOCINONIDE; FOLIC ACID; GLYCERYL TRINITRATE; KAMISTAD; LIDOCAINE; LORAMYC; MICONAZOLE; MUNDISAL; PROCHLORPERAZINE MALEATE; SOLCOSERYL; SUCRALFATE; THALIDOMIDE; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; VITAMIN B GROUP; TOPICAL ANTIINFECTIVE AGENT;

ANALGESIA; APHTHOUS STOMATITIS; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DRUG ADMINISTRATION ROUTE; DRUG DOSAGE FORM; HUMAN; LOZENGE; MOUTH MUCOSA; REVIEW; TABLET FORMULATION;

ANTI-INFECTIVE AGENTS, LOCAL; HUMANS; MOUTH MUCOSA; STOMATITIS, APHTHOUS;

EID: 84883351825     PISSN: 12107816     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Gandhi R. E., Robinson J. R. Bioadhesion in drug delivery. Ind. J. Pharm. Sci. 1988; 50, 145-152.
2. Shojaei A. H. Buccal Mucosa As A Route For Systemic Drug Delivery: A Review. J. Pharm. Pharmaceut. Sci. 1998; 1, 15-30.
3. Harris D., Robinson J. R. Drug delivery via the mucous membranes of the oral cavity. J. Pharm. Sci. 1992; 81, 1-10.
4. Wertz P.W., Squier C. A. Cellular and molecular basis of barrier function in oral epithelium. Crit. Rev. Ther. Drug. Carr. Sys. 1991; 8, 237-269.
5. Squier C. A., Cox P., Wertz P. W. Lipid content and water permeability of skin and oral mucosa. J. Invest. Dermatol. 1991; 96, 123-126.
6. Squier C. A., Wertz P. W. Structure and function of the oral mucosa and implications for drug delivery. In: Rathbone, M. J. ed. Oral Mucosal Drug Delivery. New York: Marcel Dekker Inc. 1996.
7. Galey W. R., Lonsdale H. K., Nacht S. The in vitro permeability of skin and buccal mucosa to selected drugs and tritiated water. J. Invest. Dermatol. 1976; 67, 713-717.
8. Gandhi R. B., Robinson J. R. Oral cavity as a site for bioadhesive drug delivery. Adv. Drug Deliv. Rev. 1994; 13, 43-74.
9. Tabak L. A., Levine M. J., Mandel I. D., Ellison S. A. Role of salivary mucins in the protection of the oral cavity. J. Oral. Pathol. 1982; 11, 1-17.
10. Peppas N. A., Buri P. A. Surface, interfacial and molecular aspects of polymer bioadhesion on soft tissues. J. Control. Release. 1985; 2, 257-275.
11. Rathbone M., Drummond B., Tucker I. Oral cavity as a site for systemic drug delivery. Adv. Drug. Del. Rev. 1994; 13, 1-22.
12. Scully C., Porter S. Oral mucosal disease: Recurrent aphthous stomatitis. Br. J. Oral Maxillofac. Surg. 2008; 46, 198-206.
13. Jurge S., Kuffer R., Scully C., Porter S. R. Mucosal diseases series. Number VI. Recurrent aphthous stomatitis. Oral. Dis. 2006; 12, 1-21.
14. Ship, J. A. Recurrent aphthous stomatitis - An update. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 1996; 81, 141-147.
15. Rogers R. S. Recurrent Aphthous Stomatitis: Clinical Characteristics and Associated Systemic Disorders. Sem. Cut. Med. Surg. 1997; 16, 278-283.
16. Porter S. R., Hegarty A., Kaliakatsou F., Hodgson T. A. Scully C. Reccurent Aphthous Stomatitis. Clinics Dermatol. 2000; 18, 569-578.
17. Aminabadi N. A. Recurrent aphthous stomatitis may be initiated by traumatic epithelial implantation and sustained by localized pathergic status. Med. Hypotheses. 2007; 70, 522-524.
18. Squier Ch. A., Wertz P.W. Permeability and pathophysiology of oral mucosa. Adv. Drug Deliv. Rev., 1993; 12, 13-24.
19. Scully C., Porter S. Recurrent aphthous stomatitis: current concepts of etiology, pathogenesis and management. J. Oral Pathol. Med. 2006; 18, 21-27.
20. Koybasi S., Parlak A. H., Serin E., Yilmaz F., Serin D. Recurrent aphthous stomatitis: investigation of possible etiologic factors. Am. J. Otolaryngol. 2006; 27, 229-232.
21. Shashy R. G., Ridley M. B. Aphthous ulcers: A difficult clinical entity. Am. J. Otolaryngol. 2000; 21, 389-393.
22. Chi A., Neville B. W., Krayer J. W., Gonsalves W. C. Oral manifestations of systemic disease. Am. Fam. Physician. 2010; 82, 1381-1388.
23. Bickle K. M., Roark T. R., Hsu S. Autoimmune Bullous Dermatoses: AReview. Am. Fam. Physician. 2002; 65, 1861-1871.
24. Zand N., Ataie-Fashtami L., Djavid G. E., Fateh M., Alinaghizadeh M.-R., Arbabi-Kalati F. Relieving pain in minor aphthous stomatitis by a single session of non-thermal carbon dioxide laser irradiation. Lasers Med. Sci. 2009; 24, 515-520.
25. Porter S., Scully C. Aphthous ulcers (recurrent). Clin. Evid. 2005; 13, 1687-1694.
26. Gonzalez-Garcia A., Diniz-Freitas M., Gandara-Vila P., Blanco-Carrion A., Garcia-Garcia A., Gandara-Rey J. M. Triamcinolone acetonide mouth rinses for treatment of erosive oral lichen planus: efficacy and risk of fungal over-infection. Oral Dis. 2006; 12, 559-565.
27. Gehlen I., Netuschil L., Georg T., Reich E., Berg R., Katsaros Ch. Influence of a 0.2% Chlorhexidine Mouthrinse on Plaque Regrowth in Orthodontic Patients. J. Orofac. Orthoped. 2000; 61, 138-148.
28. Kadir T., Gumru B., Uygun-Can B. Phospholipase activity of Candida albicans isolates from patients with denture stomatitis: The influence of chlorhexidine gluconate on phospholipase production. Arch. Oral Biol. 2007; 52, 691-696.
29. Dogan S., Gunay H., Leyhausen G., Geurtsen W. Effects of lowconcentrated chlorhexidine on growth of Streptococcus sobrinus and primary human gingival fibroblasts. Clin. Oral Invest. 2003; 7, 212-216.
30. Dinge A., Nagarsenker M. Formulation and Evaluation of Fast Dissolving Films for Delivery of Triclosan to the Oral Cavity. AAPS PharmSciTech. 2008; 9, 349-356.
31. Sreenivasan P. K., Gaffar A. Antibacterials as anti-inflammatory agents: Dual action agents for oral health. Antonie van Leeuwenhoek. 2008; 93, 227-239.
32. Bruhn G., Netuschil L., Richter S., Brecx M., Hoffmann T. Effect of a toothpaste containing triclosan on dental plaque, gingivitis, and bleeding on probing - an investigation in periodontitis patients over 28 weeks. Clin. Oral Invest., 2002; 6, 124-127.
33. Quane P. A., Graham G. G., Ziegler J. B. Pharmacology of benzydamin. Inflammopharmacology. 1998; 6, 95-107.
34. Cheng K. K. F. Children's acceptance and tolerance of chlorhexidine and benzydamine oral rinses in the treatment of chemotherapy-induced oropharyngeal mucositis. Eur. J. Oncol. Nursing. 2004; 8, 341-349.
35. The European Pharmacopoeia, 7th ed (7.1. Strasbourg: European Directorate for the Quality of Medicines & Health Care, 2010. Electronic resource.
36. Bonacucina G., Cespi M., Misici-Falzi M., Palmieri G. F. Rheological, adhesive and release characterisation of semisolid Carbopol/tetragylcol systems. Int. J. Pharm. 2006; 307, 129-140.
37. The International Pharmacopoeia 1st Supplement, 4th ed. Geneva: World Healthcare Organization, 2008. Electronic resource.
38. Thimmasetty J., Suresh Babu C., Udupa N. Design and evaluation of buccal drug delivery systems. Pharmag. 1996, 14-22.
39. Lee J. W., Park J. H., Robinson J. R. Bioadhesive-based dosage forms: The next generation. J. Pharmaceut. Sci. 2000; 89, 850-866.
40. Karavana S.Y., Guneri P., Ertan G. Benzydamine hydrochloride buccal bioadhesive gels designed for oral ulcers: preparation, rheological, textural, mucoadhesive and release properties. Pharm. Dev. Technol. 2009; 14, 623-631.
41. Sudhakar Y., Kuotsu K., Bandyopadhyay A. K. Buccal bioadhesive drug delivery - A promising option for orally less efficient drugs. J. Contr. Release. 2006; 114, 15-40.
42. Ludwig A. The use of mucoadhesive polymers in ocular drug delivery. Adv. Drug Deliv. Rev. 2005; 57, 1595-1639.
43. Salamat-Miller N., Chittchang M., Johnston T. P. The use of mucoadhesive polymers in buccal drug delivery. Adv. Drug Deliv. Rev. 2005; 57, 1666-1691.
44. Singh S., Jain S., Muthu M. S., Tiwari S., Tilak R. Preparation and Evaluation of Buccal Bioadhesive Films Containing Clotrimazole. AAPS PharmSciTech. 2008; 9, 660-667.
45. Charde S., Mudgal M., Kumar L., Saha R. Development and Evaluation of Buccoadhesive Controlled Release Tablets of Lercanidipine. AAPS PharmSciTech. 2008; 9, 182-190.
46. Patel V. M., Prajapati B. G., Patel M. M. Formulation, Evaluation, and Comparison of Bilayered and Multilayered Mucoadhesive Buccal Devices of Propranolol Hydrochloride. AAPS PharmSciTech. 2007; 8, E1-E8.
47. Desai K. G. H., Kumar T. M. P. Preparation and Evaluation of a Novel Buccal Adhesive System. AAPS PharmSciTech. 2004; 5, 1-9.
48. Boateng J. S., Matthews K. H., Auffret A. D., Humphrey M. J., Stevens H. N., Eccleston G. M. In vitro drug release studies of polymeric freeze-dried wafers and solvent-cast films using paracetamol as a model soluble drug. Int. J. Pharm. 2009; 378, 66-72.
49. Gajdziok J., Rabiškova M. Oralně dispergovatelne lekove formy a technologie jejich vyroby. (Orodispersable dosage forms and technologies used in their production.. Čes. a slov. Farm. 2010; 59, 251-255.
50. Cui Z., Mumper R. J. Buccal Transmucosal Delivery of Calcitonin in Rabbits Using Thin-Film Composites. Pharm. Res. 2002; 19, 1901-1906.
51. Chunbai H., Fuying C., Lichen Y., Feng Q., Cui T.Apolymeric composite carrier for oral delivery of peptide drugs: Bilaminated hydrogel film loaded with nanoparticles. Eur. Polymer J. 2009; 45, 368-376.
52. El-Kamel A. H., Ashri L. Y., Alsarra I. A. Micromatricial Metronidazole Benzoate Film as a Local Mucoadhesive Delivery System for Treatment of Periodontal Diseases. AAPS PharmSciTech. 2007; 8, E1-E11.